JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moran, N. C.
Right arrow Articles by Butler, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moran, N. C.
Right arrow Articles by Butler, W. M., Jr.
Journal of Pharmacology And Experimental Therapeutics, Vol. 125, Issue 1, 73-84, 1959
Copyright © 1959 by American Society for Pharmacology and Experimental Therapeutics


THE PHARMACOLOGICAL ACTIONS OF OXYPANAMINE, AN ALKALOID DERIVED FROM THE SEEDS OF ORMOSIA PANAMENSIS

Neil C. Moran 1, Gertrude P. Quinn 1, and William M. Butler Jr. 1

1 Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Department of Health, Education and Welfare, Bethesda 14, Maryland

Oxypanamine is a polycyclic alkaloid of undetermined structure obtained as an air oxidation product of panamine, the latter being a new alkaloid isolated from the seeds of Ormosia panamensis. Oxypanamine is believed to have an N-oxide functional group. In dogs it produces prolonged reduction of systemic blood pressure, elevated pulmonary artery pressure, bronchoconstriction, increased hematocrit, cutaneous erythema and urticaria, effects which ensue following a latent period of 30 to 120 seconds after i.v. injection. Tachyphylaxis to all of these actions is prominent Similar actions were observed in cats, guinea pigs and a chicken but not in rabbits or one monkey. The hypotensive action in dogs is not prevented by atropine or hexamethonium by bilateral section of the vagus and carotid sinus nerves or by spinal cord destruction, nor is it due to adrenergic or ganglionic blockade.

Intra-arterial injections of oxypanamine produce no direct increase in femoral artery blood flow in doses less than those which lower blood pressure when given i.v. Large intra-arterial doses produce a prolonged, delayed increase in flow simultaneously with a fall in systemic arterial pressure. It is concluded that the delayed vasodilatation occurs after the oxypanamine reaches the systemic circulation and is, therefore, an indirect action.

No significant positive or negative cardiac inotropic actions were observed in canine heartlung preparations or in dogs with intact circulatory systems in which cardiac contractile force was measured directly with a strain gauge arch. No efects on the ECG were observed except at the lethal dose, and the changes noted then were attributed to anoxia.

Oxypanamine produces neuromuscular blockade in dogs and chickens similar to the caused by d-tubocurarine. On the basis of a rabbit head-drop assay oxypanamine was found to be about frac18 as active as d-tubocurarine. Ganglionic blockade can be demonstrated with very high doses of oxypanamine in dogs and cats maintained under artificial respiration.

Oxypanamine produces other action in dogs such as piloerection, mild sedation, ataxia and potentiation of barbiturate anesthesia. However, no sedation or potentiation of hexobarbital was observed in rats.

A conmparison of the actions of oxypanamine, panamine, N-methylpanamine and the N-oxide of N-methylpanamine has been made. The importance of the presumed N-oxide functional group for both histamine-like and neuromuscular blocking actions is emphasized.

Submitted on September 5, 1958







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1959 by the American Society for Pharmacology and Experimental Therapeutics.